Shares of Mesoblast Limited (NASDAQ:MESO - Get Free Report) reached a new 52-week high during mid-day trading on Monday . The company traded as high as $20.97 and last traded at $20.75, with a volume of 322856 shares. The stock had previously closed at $17.53.
Analyst Ratings Changes
Several analysts have commented on the stock. Jefferies Financial Group lowered shares of Mesoblast from a "buy" rating to a "hold" rating in a report on Monday, December 23rd. Maxim Group upgraded Mesoblast from a "hold" rating to a "buy" rating and set a $12.00 price target on the stock in a research report on Tuesday, September 24th. Piper Sandler raised their price objective on Mesoblast from $11.00 to $15.00 and gave the company an "overweight" rating in a research report on Thursday, December 19th. Finally, StockNews.com cut shares of Mesoblast from a "hold" rating to a "sell" rating in a report on Wednesday, September 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Mesoblast currently has a consensus rating of "Hold" and a consensus price target of $13.50.
View Our Latest Stock Report on MESO
Mesoblast Stock Performance
The business has a 50 day moving average price of $11.47 and a 200 day moving average price of $8.75. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21.
Institutional Investors Weigh In On Mesoblast
A number of institutional investors have recently made changes to their positions in the company. Rathbones Group PLC bought a new position in shares of Mesoblast during the second quarter valued at $95,000. XTX Topco Ltd bought a new stake in Mesoblast in the 2nd quarter worth approximately $103,000. Marshall Wace LLP purchased a new stake in Mesoblast during the 2nd quarter valued at $562,000. Lazari Capital Management Inc. lifted its holdings in shares of Mesoblast by 6.6% during the 2nd quarter. Lazari Capital Management Inc. now owns 53,467 shares of the company's stock valued at $364,000 after buying an additional 3,300 shares during the period. Finally, Perkins Coie Trust Co boosted its stake in shares of Mesoblast by 15.0% in the 3rd quarter. Perkins Coie Trust Co now owns 11,500 shares of the company's stock worth $94,000 after buying an additional 1,500 shares during the last quarter. Hedge funds and other institutional investors own 1.43% of the company's stock.
About Mesoblast
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
See Also
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
